ResearchFDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas
ResearchMinimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective
ResearchOutcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
ResearchOutcomes of Burkitt Lymphoma with Central Nervous System Involvement: Evidence from a Large Multicenter Cohort Study
ResearchAssessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
ResearchA Retrospective Comparison of Venetoclax Alone or in Combination with an Anti-CD20 Monoclonal Antibody in R/R CLL
ResearchCombinations or Sequences of Targeted Agents in CLL: Is the Whole Greater Than the Sum of Its Parts?
ResearchFDA Approval Summary Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas